Andrew Yee
Massachusetts General Hospital · Massachusetts General Hospital, Boston
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Yee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07247097 · ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple MyelomaMassachusetts General Hospital · not yet recruiting · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible · principal investigator
- Ph2NCT05922501 · Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaMassachusetts General Hospital · recruiting · Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma · principal investigator
- Ph2NCT04119336 · Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaAndrew Yee, MD · terminated · Relapsed Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph2NCT04009109 · Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · active not recruiting · Myeloma, Multiple · study chair
- Ph1NCT01582295 · XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseMassachusetts General Hospital · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:46 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- 433 citationsRCR 32.2
- A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury.J Neurotrauma · 2011190 citationsRCR 5.8
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.Lancet Oncol · 2016172 citationsRCR 5.3
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.J Clin Oncol · 2018156 citationsRCR 4.5
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.Br J Haematol · 2018147 citationsRCR 5.0
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.J Clin Oncol · 2018140 citationsRCR 4.6
- Global connectivity and local excitability changes underlie antidepressant effects of repetitive transcranial magnetic stimulation.Neuropsychopharmacology · 2020128 citationsRCR 8.3
- Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.J Neurotrauma · 202378 citationsRCR 11.7
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.Blood Adv · 202377 citationsRCR 5.8